AXIM BIOTECHNOLOGIES, INC.

Axim Biotechnologies, Inc. develops point-of-care diagnostic healthcare solutions focused on rapid lateral flow immunoassays. The company operates primarily in eye health diagnostics, offering FDA-cleared tear tests for dry eye disease biomarkers, including Lactoferrin and Immunoglobulin E, paired with portable digital readers. Axim also maintains diagnostic assays developed for SARS-CoV-2 neutralizing antibodies and works on additional tests for biomarkers such as MMP-9. The company provides its diagnostic systems to ophthalmologists and optometrists to assist clinicians and eye care technicians in identifying and treating ocular surface conditions.

The company focuses its ophthalmic business in the United States, targeting medical eye examinations across tens of thousands of eye care specialists. It distributes its diagnostic systems and consumables globally through an exclusive partnership with Verséa Ophthalmics and procures its portable test strip readers from a supplier in Barcelona, Spain. Axim Biotechnologies maintains laboratory facilities in San Diego, California, where its principal executive office is also located.

Summary of the business section of Axim Biotechnologies's latest annual report, written by StockData.

“As of December 31, 2023, we had six full-time employees and one part-time employee.”